anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A non-aqueous cleansing formulation having cleansing, moisturizing and/or exfoliating properties includes an oil phase and a natural surfactant derived from legumes and/or grains. The oil phase can include an oil component and a thickening agent. The natural surfactant can be in the form of a particulate flour product derived from  Vigna radiala, Vigna mungo, Glycine max, Cicer aerientinum, Vigna unguicalata, Pisum sativum, Phaseolus vulgaris,  or combinations thereof, which is dispersed in the oil phase. The flour product suitably includes a high protein flour to emulsify the oil phase and provide improved cleansing action. Such non-aqueous cleansing formulation can be used as skin care products, hand cleansers, hair cleaners or general use cleansers. Advantageously, the cleansing formulations are free of synthetic soaps and/or synthetic surfactants.
Objective Post Injury concussion and headache are problematic for children after mild traumatic brain injuries. There are no evidence based guidelines for the management of acute post concussive headache. The objectives of this study were to assess the efficacy of routine administration of analgesia on concussion headache and classify headaches using the IHS criteria.

Method A 4 arm open label pilot RCT study was conducted. The treatment arms were: (i) acetaminophen,(ii) ibuprofen, (iii) acetaminophen and ibuprofen and (iv) a standard control group. Eight to eighteen year olds presenting to emergency with headache 24-48 hours after their first concussion were recruited consecutively and sequentially randomized. Demographic data was collected, headache survey administered and standard concussion education given. Headaches were diarized over one week capturing the (i) number of headaches, (ii) headache days,(iii) headache intensity and (iv) return to school.
PURPOSE:To increase a bone growth speed after filling, by compounding a specific amount of a calcium hydroxide or calcium oxide powder with an alpha- tricalcium phosphate powder. CONSTITUTION:A calcium hydroxide or calcium oxide powder is compounded with an alpha-tricalcium phosphate powder in an amount of 50% or less by wt. of the latter or in an amount of 80 equivalent % or more based on the sum of the number of the acid equivalents of a curing liquid. When the compound ratio of the calcium hydroxide or calcium oxide powder to the alpha-tricalcium phosphate powder exceeds 50wt.%, a kneaded mixture having flowability is not obtained when the powder agent is kneaded with the curing liquid and the filling workability to the omitted part or gap part of a bone or tooth becomes inferior. When said compounding ratio is below 80 equivalent % based on the sum of the number of the acid equivalents of the curing liquid, it is unpref. since calcium hydroxide or calcium oxide generates the neutralizing reaction with the curing liquid to be lost from a cured substance and the stimulation for forming secondary hard tissue lowers.
The invention relates to a traditional Chinese medicine for treating senile insomnia. The traditional Chinese medicine is prepared from the following raw material herbs in parts by weight: 12 parts of radix rehmanniae preparata, 8 parts of radix paeoniae alba, 15 parts of radix astragali preparata and 6 parts of jasmine. The inventor believes that deficiency of liver-yin and kidney-yin and hyperaction of liver yang are main etiology and pathogenesis of Zang-Fu function declination of the aged. According to the prescription, radix rehmanniae preparata is taken as the emperor to nourishing kidney-yin, supplement blood and enrich essence and fill marrow; radix paeoniae alba is taken as the subject to nourish blood and liver; radix astragali preparata is used together to regulate the middle warmer and tonify qi, and jasmine can reduce stagnation-syndrome and repel foulness to relieve nightmare distress. All the raw material herbs are used together to take the effects of nourishing kidney yin, nourishing blood and liver, enriching essence and filling marrow, regulating the middle warmer and tonifying qi, and reducing stagnation-syndrome and repelling foulness. Clinical experiments testify that the traditional Chinese medicine can safely and effectively treat senile insomnia.
Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. They will be done similar cognitive activities during with this simple balance trainings.
Provided are a long-acting sustained-release pramipexole preparation and a method for preparing same. The long-acting sustained-release pramipexole preparation comprises pramipexole pamoate or pramipexole palmitate, and a polylactic acid-glycolic acid copolymer or polylactic acid. The drug loading capacity of the preparation is 10% -50%. The molar ratio of lactic acid to glycolic acid of the polylactic acid-glycolic acid copolymer is 85:15-95:5. The microsphere is round in shape, smooth in surface and free of pores, and can effectively reduce the early burst release of the drug and solve the problem of high burst release of existing pramipexole pamoate microspheres. Also, the present invention features an effectively prolonged sustained-release period that solves the problem of the short release period of the existing pramipexole pamoate microspheres, and a smaller blood concentration fluctuation that leads to a more stable release.
BACKGROUND: To date, there is no consensus on how to standardize the assessment of ototoxicity in serial measurements. For the diagnosis of damage to the cochlear amplifier, measurement methods are required that have the highest possible test-retest reliability and validity for detecting persistent damage. Estimated distortion-product thresholds (LEDPT) based on short-pulse distortion-product otoacoustic emission (DPOAE) level maps use individually optimal DPOAE stimulus levels and allow reliable quantitative estimation of cochlea-related hearing loss.
MATERIALS AND METHODS: Hearing thresholds were estimated objectively using LEDPT and subjectively using modified Békésy tracking audiometry (LTA). Recordings were performed seven times within three months at 14 frequencies (f2 = 1-14 kHz) in 20 ears (PTA4 (0.5-4 kHz) < 20 dB HL). Reconstruction of the DPOAE growth behavior as a function of the stimulus levels L1, L2 was performed on the basis of 21 DPOAE amplitudes. A numerical fit of a nonlinear mathematical function to the three-dimensional DPOAE growth function yielded LEDPT for each stimulus frequency. For the combined analysis, probability distributions of hearing thresholds (LTA, LEDPT), DPOAE levels (LDP), and combinations thereof were determined.
RESULTS: LTA and LEDPT each exhibited a test-retest reliability with a median of absolute differences (AD) of 3.2 dB and 3.3 dB, respectively. Combining LEDPT, LDP, and LTA into a single parameter yielded a significantly smaller median AD of 2.0 dB.
CONCLUSION: It is expected that an analysis paradigm based on a combination of LEDPT, suprathreshold LDP, and fine-structure-reduced LTA would achieve higher test performance (sensitivity and specificity), allowing reliable detection of pathological or regenerative changes in the outer hair cells.
Sleep problems are common in neurological conditions for which ketogenic dietary therapies (KDTs) are recognised as an effective intervention (drug-resistant epilepsy, autism spectrum disorder, and migraine). Given the composite framework of action of ketogenic dietary therapies, the prevalence of sleep disturbance, and the importance of sleep regulation, the present scoping review aimed at identifying and mapping available evidence of the effects of ketogenic dietary therapies on sleep. A comprehensive web-based literature search was performed retrieving publications published to June 2023 using PubMed and Scopus, yielding to 277 records. Twenty papers were finally selected and included in the review. Data were abstracted by independent coders. High variability was identified in study design and sleep outcome evaluation among the selected studies. Several changes in sleep quality and sleep structure under ketogenic dietary therapies were found, namely an improvement of overall sleep quality, improvement in the difficulty falling asleep and nighttime awakenings, improvement in daytime sleepiness and an increase of REM sleep. The relevance and possible physiological explanations of these changes, clinical recommendations, and future directions in the field are discussed.
Currently the practice of minimizing monetary and human costs of therapy in the field of oncology is in vogue. As such, there has been heightened interest in the ability to decrease the total number and duration of radiation therapy treatments via brachytherapy and stereotactic body radiation therapy (SBRT). With this, the use of SBRT has been increasingly utilized for elective nodal irradiation (ENI) to treat patients with intermediate-risk prostate cancer or higher to improve biochemical progression free survival (bPFS). However, there is a dearth of studies assessing the efficacy and toxicity profile of these two modalities in combination. The objective of this phase I/II trial is to prospectively evaluate the toxicity and therapeutic efficacy of SBRT to prostate and pelvic lymph nodes in combination with high-dose-rate (HDR) brachytherapy to the prostate in patients with localized unfavorable-intermediate risk or higher disease. We hypothesize that this combination therapy will have an acceptable toxicity profile and that ENI via SBRT will provide improved bPFS compared to no nodal treatment and synonymous with conventional fractionation. The sample size will be 53 patients, with biopsy confirmed unfavorable-intermediate or higher risk prostate cancer and ≥ 15% probability of nodal involvement as determined by publicly available nomograms. Eligible patients will undergo ultrasound-guided HDR brachytherapy to the whole prostate to a dose of 15 Gy in 1 fractions followed by SBRT to a dose of 25 Gy in 5 fractions given every other day. Follow-up will assess toxicity and biochemical progression-free survival and subsequent comparison to historical results.
OBJECTIVE: To investigate the prevalence of DD and AI with POP symptoms in females attending a urogynecology clinic, and to identify factors associated with DD and AI in POP symptoms patients.
METHODS: Computer-based medical records of women with POP symptoms attending a urogynecology clinic in a referral tertiary center between January 2016 and December 2020 were reviewed. Demographic data were collected. Selected defecatory dysfunction (DD) and anal incontinence (AI) were recorded. The associations between patient characteristics, site and severity of prolapse, and DD and AI symptoms in POP patients were investigated for identified associated factors.
RESULTS: The mean age of the 754 participants was 65.77 ± 9.44 years. Seven hundred and fifteen (94.83%) were menopause. The prevalence of DD and AI in patients with POP symptoms was 44.03% (332/754) and 42.04% (317/754) according to the PFBQ and medical history records, respectively. Advanced posterior wall prolapse (OR 1.59, 95% CI 1.10-2.30) and wider GH (OR1.23, 95% CI 1.05-1.43) were identified as risk factors for DD by multivariate analysis. Additionally, single-compartment prolapse (OR 0.4, 95% CI 0.21-0.76) and a stronger pelvic floor muscle assessed with brink score (OR 0.94, 95% CI 0.88-0.98) are protective factors for AI.
CONCLUSION: DD and AI are prevalent among women with POP symptoms who visit a urogynecology clinic. DD should be evaluated in women with POP symptoms especially in women with increased genital hiatus and point Ap beyond the hymen. To prevent AI, women with POP should be encouraged to perform pelvic floor muscle training in order to increase pelvic floor muscle strength.
Patients should be counseled that antibacterial drugs, including Tazicef (ceftazidime), should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Tazicef (ceftazidime) is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Tazicef (ceftazidime) or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible.
After recruitment during 24-28 weeks of gestation, women would be given three placebo tablets per day until delivery. After delivery of the baby, the participants would be asked to take two placebo tablets per day up to six weeks postpartum.
Participants will be instructed with a 10 minute lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
Chronic stress is a common cause of hair loss, involving inflammatory responses and changes in cellular signaling pathways. This study explores the mechanism of action of the SDF-1/CXCR4 signaling axis in chronic stress-induced hair loss. The research indicates that SDF-1 promotes hair follicle growth through the PI3K/Akt and JAK/STAT signaling pathways. Transcriptome sequencing analysis was conducted to identify differentially expressed genes in the skin of normal and stressed mice, with key genes SDF-1/CXCR4 selected through machine learning and a protein-protein interaction network established. A chronic stress mouse model was created, with injections of SDF-1 and AMD3100 administered to observe hair growth, weight changes, and behavioral alterations and validate hair follicle activity. Skin SDF-1 concentrations were measured, differentially expressed genes were screened, and pathways were enriched. Activation of the PI3K/Akt and JAK/STAT signaling pathways was assessed, and siRNA technology was used in vitro to inhibit the expression of SDF-1 or CXCR4. SDF-1 promoted hair follicle activity, with the combined injection of SDF-1 and AMD3100 weakening this effect. The activation of the PI3K/Akt and JAK/STAT signaling pathways was observed in the SDF-1 injection group, confirmed by Western blot and immunofluorescence. Silencing SDF-1 through siRNA-mediated inhibition reduced cell proliferation and migration abilities. SDF-1 promotes hair growth in chronic stress mice by activating the PI3K/Akt and JAK/STAT pathways, an effect reversible by AMD3100. The SDF-1/CXCR4 axis may serve as a potential therapeutic target for stress-induced hair loss.
Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
The invention belongs to the technical field of medicines, and discloses a preparation method of an oxymatrine active targeting lipidosome. The active targeting oxymatrine lipidosome is prepared by a pH gradient method. The optimal prescription for preparing the oxymatrine active targeting lipidosome is as follows: the ratio of medicine to lipidosome is 1:10, the ratio of phospholipid to cholesterol is 3:1 with additionally 10% mol of Lac-PE, the pH value of the outer aqueous phase is 6.8, the incubation temperature is 60 DEG C, and the average encapsulation efficiency is 55.48% under the optimal prescription. The oxymatrine active targeting lipidosome prepared by the method provided by the invention is relatively stable. In vitro drug release experiments of the active targeting lipidosome show that oxymatrine wrapped by the glycosylated lipidosome has a slow release effect. Through observation by a transmission electron microscope, the oxymatrine active targeting lipidosome prepared by the method provided by the invention is a single chamber lipidosome with the average grain size of 80nm, and meets the demand of lipidosome. In vitro dissolution experiments show that the oxymatrine active targeting lipidosome wrapped has a certain slow release feature.
PURPOSE: To prepare a solid nonaqueous powdery cosmetic, containing a cyclic silicone and a silicone-based surfactant and a hydrophobic powder, capable of preventing messy makeup and having a refreshing feeling of use. CONSTITUTION: This cosmetic contains 1-5 wt.% cyclic silicone of the formula [R<1> and R<2> are each an alkyl or an alkenyl; (m) is 6], 0.1-20wt.% silicone-based surfactant (e.g. a polyether-modified silicone) and 30-96 wt.% hydrophobic powder (e.g. a nylon powder) as active ingredients. The adhesion of the hydrophobic powder to the hydrophilic skin is improved and removal due to the moisture of perspiration, etc., is reduced by adding the silicone-based surfactant to the hydrophobic powder. The safe cyclic silicone readily volatilizing by skin temperature or contact with air can further be added to thereby prevent the cosmetic from being removed and the face from shining due to the secretion of sebum with time.
A method and system is provided for assisting a user to assign a label to words or spans of text in a transcript of a conversation between a patient and a medical professional and form groupings of such labelled words or spans of text in the transcript. The transcript is displayed on an interface of a workstation. A tool is provided for highlighting spans of text in the transcript consisting of one or more words. Another tool is provided for assigning a label to the highlighted spans of text. This tool includes a feature enabling searching through a set of predefined labels available for assignment to the highlighted span of text. The predefined labels encode medical entities and attributes of the medical entities. The interface further includes a tool for creating groupings of related highlighted spans of texts. The tools can consist of mouse action or key strokes or a combination thereof.
Polyphenols are compounds of plant origin with several documented bioactivities related to health promotion. Some polyphenols are hard to be absorbed into the body due to their structural characteristics. This review focuses on the health beneficial effects of polyphenols mediated by intestinal hormones, particularly related to the systemic functions through the secretion of glucagon-like peptide-1 (GLP-1), an enteric hormone that stimulates postprandial insulin secretion. GLP-1 is secreted from L cells in the distal small intestine. Therefore, some poorly absorbed polyphenols are known to have the ability to act on the intestines and promote GLP-1 secretion. It has been reported that it not only reduces hyperglycemia but also prevents obesity by reduction of overeating and improves blood vessel function. This review discusses examples of health effects of polyphenols mediated by GLP-1 secretion.
Recently, there has been growing interest in using cell therapy through core decompression (CD) to treat osteonecrosis of the femoral head (ONFH). Our study aimed to investigate the effectiveness and mechanism of human umbilical cord mesenchymal stem cells (hUCMSCs) in treating steroid-induced ONFH. We constructed a steroid-induced ONFH rabbit model as well as dexamethasone (Dex)-treated bone microvascular endothelial cells (BMECs) model of human femoral head. We injected hUCMSCs into the rabbit femoral head via CD. The effects of hUCMSCs on steroid-induced ONFH rabbit model and Dex-treated BMECs were evaluated via micro-CT, microangiography, histology, immunohistochemistry, wound healing, tube formation, and western blotting assay. Furthermore, we conducted single-cell RNA sequencing (scRNA-seq) to examine the characteristics of endothelial cells, the activation of signaling pathways, and inter-cellular communication in ONFH. Our data reveal that hUCMSCs improved the femoral head microstructure and bone repair and promoted angiogenesis in the steroid-induced ONFH rabbit model. Importantly, hUCMSCs improved the migration ability and angioplasty of Dex-treated BMECs by secreting COL6A2 to activate FAK/PI3K/AKT signaling pathway via integrin α1β1.
This protocol uses the recommended World Health Organization (WHO) protocol for monitoring antimalarial efficacy. Patients with malaria will receive supervised therapy and will be monitored for 28 days to check for treatment response, both clinically and parasitologically. A total of 81 participants ≥5 years old with parasitological confirmation of P. falciparum monoinfection will be treated under supervision with artemether-lumefantrine for three days, with doses according to the Brazilian guidelines for malaria control. The clinical and parasitological parameters will be monitored for a 28-day follow-up period to evaluate the efficacy of the combination therapy. Patients will be asked to come back on Days 2, 3, 7, 14, 21 and 28 for clinical evaluation and blood tests using microscopy. A blood sample will be collected on filter paper on the first day and on the day of suspected failure to try to differentiate the parasite genotypes using techniques based on polymerase chain reactions, this will allow us to determine if the recurrent infection was reinfection or failure or recrudescence. Results of this evaluation will guide treatment policies in Brazil.
Dexamethasone will be administered 30 minutes before the anesthetic induction. Paracetamol will be administered at the end of the surgery.
Of the total number of subjects in the clinical trials (5,415), buprenorphine transdermal system was administered to 1,377 patients aged 65 years and older. Of those, 457 patients were 75 years of age and older. In the clinical program, the incidences of selected buprenorphine transdermal system-related AEs were higher in older subjects. The incidences of application site AEs were slightly higher among subjects < 65 years of age than those ≥ 65 years of age for both buprenorphine transdermal system and placebo treatment groups.

In a single-dose study of healthy elderly and healthy young subjects treated with buprenorphine transdermal system 10 mcg/hour, the pharmacokinetics were similar. In a separate dose-escalation safety study, the pharmacokinetics in the healthy elderly and hypertensive elderly subjects taking thiazide diuretics were similar to those in the healthy young adults. In the elderly groups evaluated, adverse event rates were similar to or lower than rates in healthy young adult subjects, except for constipation and urinary retention, which were more common in the elderly. Although specific dose adjustments on the basis of advanced age are not required for pharmacokinetic reasons, use caution in the elderly population to ensure safe use [see Clinical Pharmacology (12.3)].

Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of buprenorphine transdermal system slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.10)].